These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8719556)

  • 21. Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients.
    Jacobs C
    Nat Clin Pract Nephrol; 2006 Oct; 2(10):552-3. PubMed ID: 17003830
    [No Abstract]   [Full Text] [Related]  

  • 22. [Iron metabolism in patients treated with erythropoietin].
    Ksiazek
    Przegl Lek; 1995; 52(3):85. PubMed ID: 7644679
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
    Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
    Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Improving the administration of erythropoietin].
    Suszko P; Rousseau S; Poite O
    Soins; 2007 Oct; (719 Suppl):S22-3. PubMed ID: 18050874
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
    Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
    [No Abstract]   [Full Text] [Related]  

  • 26. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
    Cuero CJ; Pérez Guardia E; de Rivera C
    Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group.
    Raftery MJ; Auinger M; Hertlová M
    Clin Nephrol; 2000 Sep; 54(3):240-5. PubMed ID: 11020023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should target hemoglobin levels in dialysis patients be lowered to 9-10 g/dl?
    Fishbane S; Masani NN; Hazzan AD
    Semin Dial; 2014; 27(3):282-4. PubMed ID: 24666175
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
    Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
    Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
    [No Abstract]   [Full Text] [Related]  

  • 31. Influence of the treatment with recombinant human erythropoietin on plasma concentration of interleukin-1-alpha and tumour necrosis factor-alpha in hemodialyzed subjects.
    Buemi M; Allegra A; Aloisi C; Privitera M; Morabito N; Frisina N
    Nephron; 1993; 64(2):333-4. PubMed ID: 8321378
    [No Abstract]   [Full Text] [Related]  

  • 32. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human erythropoietin and haemodialyser re-use.
    Dos Santos JP; Prata MM; Sousa FT; Barbas JV
    Nephron; 1990; 56(4):447-8. PubMed ID: 2080010
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life in the era of erythropoietin.
    Weisbord SD; Kimmel PL
    Hemodial Int; 2008 Jan; 12(1):6-15. PubMed ID: 18271834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothyroidism and resistance to human recombinant erythropoietin.
    Touam M; Guéry B; Goupy C; Menoyo V; Drüeke T
    Nephrol Dial Transplant; 2004 Apr; 19(4):1020-1. PubMed ID: 15031379
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of low doses of recombinant human erythropoietin on the anemia in hemodialyzed patients.
    Okada K; Takahashi S
    Nephron; 1991; 59(4):689-90. PubMed ID: 1766524
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietin, oxidative metabolism and dialysis.
    Ionova D; Sepetlieva K; Tcachev K
    Nephron; 2000 Dec; 86(4):544. PubMed ID: 11124624
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of erythropoietin administration on thyroid functions of the patients undergoing regular hemodialysis.
    Seyrek N; Paydas S; Sagliker Y
    Nephron; 1996; 72(4):714-5. PubMed ID: 8730452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.